How can small firms benefit from open innovation? the case of new drug development in Taiwan

Yu Shan Su, Hsin Yi Hu, Feng Shang Wu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

How can small firms manage and benefit from open innovation? We study three Taiwan's biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin's team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.

Original languageEnglish
Pages (from-to)61-82
Number of pages22
JournalInternational Journal of Technology Management
Volume72
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Taiwan
Innovation
innovation
drug
firm
Industry
university teacher
pharmaceutical
Drug products
technology transfer
biotechnology
Drug development
Open innovation
Small firms
Drugs
Technology transfer
Biotechnology
corporation
Japan
Pharmaceuticals

Keywords

  • Biotechnology firms
  • External partners
  • New drug development
  • Open innovation
  • Small firms
  • Taiwan

ASJC Scopus subject areas

  • Industrial relations
  • Engineering(all)
  • Computer Science Applications
  • Strategy and Management
  • Law

Cite this

How can small firms benefit from open innovation? the case of new drug development in Taiwan. / Su, Yu Shan; Hu, Hsin Yi; Wu, Feng Shang.

In: International Journal of Technology Management, Vol. 72, No. 1, 01.01.2016, p. 61-82.

Research output: Contribution to journalArticle

@article{0811f51820c7439e89d64bfd798a992c,
title = "How can small firms benefit from open innovation? the case of new drug development in Taiwan",
abstract = "How can small firms manage and benefit from open innovation? We study three Taiwan's biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin's team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.",
keywords = "Biotechnology firms, External partners, New drug development, Open innovation, Small firms, Taiwan",
author = "Su, {Yu Shan} and Hu, {Hsin Yi} and Wu, {Feng Shang}",
year = "2016",
month = "1",
day = "1",
doi = "10.1504/IJTM.2016.080551",
language = "English",
volume = "72",
pages = "61--82",
journal = "International Journal of Technology Management",
issn = "0267-5730",
publisher = "Inderscience Enterprises Ltd",
number = "1",

}

TY - JOUR

T1 - How can small firms benefit from open innovation? the case of new drug development in Taiwan

AU - Su, Yu Shan

AU - Hu, Hsin Yi

AU - Wu, Feng Shang

PY - 2016/1/1

Y1 - 2016/1/1

N2 - How can small firms manage and benefit from open innovation? We study three Taiwan's biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin's team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.

AB - How can small firms manage and benefit from open innovation? We study three Taiwan's biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin's team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.

KW - Biotechnology firms

KW - External partners

KW - New drug development

KW - Open innovation

KW - Small firms

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=85002773021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002773021&partnerID=8YFLogxK

U2 - 10.1504/IJTM.2016.080551

DO - 10.1504/IJTM.2016.080551

M3 - Article

AN - SCOPUS:85002773021

VL - 72

SP - 61

EP - 82

JO - International Journal of Technology Management

JF - International Journal of Technology Management

SN - 0267-5730

IS - 1

ER -